Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04338295 · ClinicalTrials.gov registry record · NA
Follicular Revival in Treatment-resistant Alopecia Areata: Evaluating Use of Micro-needling
A NA study, sponsored by Yale University.
- Completed
- Registry status
- NA
- Development phase
- 5
- Enrollment target
NCT04338295: Completed NA study, sponsored by Yale University.
NCT04338295 is a NA study that has completed, run by Yale University. The registered enrollment target is 5 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04338295, a NA study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- NA
- Development phase
- 5 participants
- Enrollment target
Study Summary
The investigators propose to study the efficacy of micro-needling via the SOL Nova Device in generating hair growth in patients with Alopecia Areta (AA) who are either non-responsive or only partially responsive to combination oral JAK inhibitor plus oral minoxidil therapy.
Primary Outcome
Total number of hairs in the area that undergoes microneedling
Interventions
- DEVICE Tattoo machine (SOL Nova Device)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2021-04-09 |
| Est. Completion | 2022-05-16 |
| Phase | NA |
What the finished NCT04338295 record still lists
NCT04338295 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 1 intervention - of which Tattoo machine (SOL Nova Device) is the first listed.
NCT04338295 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04338295 about?
NCT04338295 is a clinical study titled "Follicular Revival in Treatment-resistant Alopecia Areata: Evaluating Use of Micro-needling". The investigators propose to study the efficacy of micro-needling via the SOL Nova Device in generating hair growth in patients with Alopecia Areta (AA) who are either non-responsive or only partially responsive to combination oral JAK inhibitor plus oral minoxidil therapy.
What is the current status of trial NCT04338295?
This trial is currently completed. It is a NA study. The enrollment target is 5 participants. The study started on 2021-04-09. Estimated completion is 2022-05-16.
What interventions are being tested in trial NCT04338295?
The interventions under investigation include: Tattoo machine (SOL Nova Device) (DEVICE).
Who is sponsoring clinical trial NCT04338295?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04338295's enrollment target sits among peer trials
5 1988th of 2000 higher than 5 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI